---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017852"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:44:09.037160+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q1 revenue $100.5M (+26% YoY); net loss $164M; reaffirms FY 2023 guidance

## Summary
- Crysvita revenue $76M (+28% YoY), Dojolvi $14.3M (+15%), Mepsevii $8.5M.
- Net loss per share $2.33 vs $2.19 in Q1 2022; op ex $254.6M incl $31.9M stock comp.
- Cash & equivalents $714.6M; reaffirms FY 2023 total revenue $425-450M, net cash used <$400M.
- UX143 OI Phase 2 complete, data & Phase 3 initiation expected mid-2023.
- GTX-102 expansion cohorts dosing; next data update in 2H 2023.

## SEC filing metadata
- accession: 0000950170-23-017852
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017023017852/0000950170-23-017852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017023017852/rare-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017852
- JSON: https://secwatch.observer/filing/0000950170-23-017852.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017852.txt

## Key facts
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported First Quarter 2023 results: revenue $ 100,496, net income $ (163,972 ), EPS $ (2.33 ). Guidance reaffirmed.
  - Period: First Quarter 2023
  - Revenue: $ 100,496
  - Net income: $ (163,972 )
  - EPS: $ (2.33 )
  - Guidance: reaffirmed
  - Result: reported results
  source text: Selected Financial Data (dollars in thousands, except per share amounts), (unaudited) Three Months Ended March 31, 2023 2022 Total revenues $ 100,496 $ 79,935 Operating expense: Cost of sales 12,257 6,100 Research and development 165,698 143,155 Selling, general and administrative 76,646 67,312 Total operating expense 254,601 216,567 Net loss $ (163,972 ) $ (152,320 ) Net loss per share, basic and diluted $ (2.33 ) $ (2.19 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023017852/0000950170-23-017852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.